EE04452B1 - Farmatseutiliselt aktiivne morfolinool ja selle kasutamine - Google Patents

Farmatseutiliselt aktiivne morfolinool ja selle kasutamine

Info

Publication number
EE04452B1
EE04452B1 EEP200000438A EEP200000438A EE04452B1 EE 04452 B1 EE04452 B1 EE 04452B1 EE P200000438 A EEP200000438 A EE P200000438A EE P200000438 A EEP200000438 A EE P200000438A EE 04452 B1 EE04452 B1 EE 04452B1
Authority
EE
Estonia
Prior art keywords
pharmaceutically active
morpholinol
active morpholinol
pharmaceutically
active
Prior art date
Application number
EEP200000438A
Other languages
English (en)
Estonian (et)
Inventor
Frederick Morgan Phillip
Lee Musso David
Joseph Partridge John
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of EE200000438A publication Critical patent/EE200000438A/xx
Publication of EE04452B1 publication Critical patent/EE04452B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200000438A 1998-01-21 1999-01-20 Farmatseutiliselt aktiivne morfolinool ja selle kasutamine EE04452B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9801230.5A GB9801230D0 (en) 1998-01-21 1998-01-21 Pharmaceutically active morpholinol
US7218098P 1998-01-22 1998-01-22
PCT/US1999/001134 WO1999037305A1 (fr) 1998-01-21 1999-01-20 Morpholinol pharmaceutiquement actif

Publications (2)

Publication Number Publication Date
EE200000438A EE200000438A (et) 2001-12-17
EE04452B1 true EE04452B1 (et) 2005-04-15

Family

ID=26312986

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000438A EE04452B1 (et) 1998-01-21 1999-01-20 Farmatseutiliselt aktiivne morfolinool ja selle kasutamine

Country Status (30)

Country Link
US (2) US6274579B1 (fr)
EP (2) EP1047428B1 (fr)
JP (1) JP2002501025A (fr)
KR (1) KR100568063B1 (fr)
CN (2) CN1203858C (fr)
AP (1) AP1229A (fr)
AT (1) ATE365042T1 (fr)
AU (1) AU755536B2 (fr)
BR (1) BR9907203A (fr)
CA (1) CA2318268A1 (fr)
CY (1) CY1106828T1 (fr)
DE (1) DE69936335T2 (fr)
DK (1) DK1047428T3 (fr)
EA (1) EA002410B1 (fr)
EE (1) EE04452B1 (fr)
ES (1) ES2288012T3 (fr)
HR (2) HRP20000494B1 (fr)
HU (1) HUP0100900A3 (fr)
ID (1) ID26334A (fr)
IL (2) IL161942A0 (fr)
IS (1) IS2494B (fr)
NO (2) NO326878B1 (fr)
NZ (3) NZ505809A (fr)
PL (1) PL193622B1 (fr)
PT (1) PT1047428E (fr)
SG (1) SG115489A1 (fr)
SK (1) SK10912000A3 (fr)
TR (1) TR200002126T2 (fr)
WO (1) WO1999037305A1 (fr)
YU (1) YU67102A (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098206B2 (en) * 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) * 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
WO1999038504A1 (fr) 1998-01-29 1999-08-05 Sepracor Inc. Utilisations pharmaceutiques de (-)-bupropion optiquement pur
AU2349999A (en) * 1998-01-29 1999-08-16 Sepracor, Inc. Pharmacological uses of pure (+) -bupropion
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
EP1220673A2 (fr) * 1999-10-13 2002-07-10 Glaxo Group Limited Methode destinee au traitement de l'obesite
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US7145649B2 (en) * 2000-12-21 2006-12-05 Brasscorp Limited Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing
US6979104B2 (en) 2001-12-31 2005-12-27 R.J. Doran & Co. LTD LED inspection lamp
CN1320886C (zh) * 2002-05-17 2007-06-13 杜克大学 安非他酮与抗惊厥药在制备治疗肥胖症的药物的用途
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
GB0219687D0 (en) * 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
DE60324685D1 (de) * 2002-08-23 2008-12-24 Lilly Co Eli 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin-wiederaufnahme-inhibitoren
PL2316456T3 (pl) * 2003-04-29 2017-12-29 Orexigen Therapeutics, Inc. Kompozycje wpływające na utratę masy zawierające antagonistę opioidów i bupropion
US20070093486A1 (en) * 2003-10-27 2007-04-26 Smith Kline Beecham Corporation ,Corporation Enzyme-catalyzed dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinoland salts and solvates thereof
GB0325055D0 (en) * 2003-10-27 2003-12-03 Smithkline Beecham Corp New process
GB0326148D0 (en) * 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
GB0327195D0 (en) * 2003-11-21 2003-12-24 Smithkline Beecham Corp Novel use
GB0327619D0 (en) * 2003-11-27 2003-12-31 Smithkline Beecham Corp New use
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
AU2005206139B2 (en) * 2004-01-13 2009-02-26 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
EP1748776A1 (fr) * 2004-05-03 2007-02-07 Duke University Compositions influant sur la perte de poids
FI117283B (fi) 2005-02-04 2006-08-31 Kone Corp Hissijärjestelmä
DK2135603T3 (da) 2005-11-22 2013-03-25 Orexigen Therapeutics Inc Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet
MX2008008694A (es) * 2006-01-03 2009-01-07 Algebra Inc Compuestos conjugados de amina terapeutica-arilsulfonamida.
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008060964A2 (fr) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Procédés d'administration de médications pour la perte de poids
US8088786B2 (en) 2006-11-09 2012-01-03 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations
US20090075994A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched radafaxine
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
JP5711724B2 (ja) 2009-04-15 2015-05-07 リサーチ・トライアングル・インスティチュート モノアミン再取り込み阻害剤
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
WO2011146821A2 (fr) * 2010-05-21 2011-11-24 Research Triangle Institute Analogues d'hydroxybupropion pour le traitement de la pharmacodépendance
ES2687095T3 (es) 2010-05-21 2018-10-23 Research Triangle Institute Fenilimorfolinas y análogos de las mismas
US9510405B2 (en) 2011-06-30 2016-11-29 Schneider Electric Industries Sas Dual power SMPS for a modular lighting system
CN102670617B (zh) * 2012-04-13 2013-03-20 湖南大学 布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用
ES2802048T3 (es) 2012-06-06 2021-01-15 Nalpropion Pharmaceuticals Llc Composición para uso en un método para el tratamiento de sobrepeso y obesidad en pacientes con alto riesgo cardiovascular
CN105949142B (zh) * 2016-05-21 2018-03-27 南华大学 具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) * 2021-06-17 2021-12-30 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US170430A (en) * 1875-11-30 Improvement in furnaces for heating steel in tempering
GB8417170D0 (en) * 1984-07-05 1984-08-08 Wellcome Found Heterocyclic pharmaceutical compounds
GB9108629D0 (en) 1991-04-23 1991-06-12 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use

Also Published As

Publication number Publication date
EP1047428A4 (fr) 2001-12-19
CN1528753A (zh) 2004-09-15
HUP0100900A3 (en) 2002-08-28
NZ520349A (en) 2004-02-27
TR200002126T2 (tr) 2000-12-21
EP1047428B1 (fr) 2007-06-20
EE200000438A (et) 2001-12-17
PL193622B1 (pl) 2007-02-28
KR100568063B1 (ko) 2006-04-07
DK1047428T3 (da) 2007-10-08
IL137346A0 (en) 2001-07-24
CN1203858C (zh) 2005-06-01
AU755536B2 (en) 2002-12-12
BR9907203A (pt) 2000-10-17
JP2002501025A (ja) 2002-01-15
EP1829544A1 (fr) 2007-09-05
NO20003721L (no) 2000-09-19
DE69936335D1 (de) 2007-08-02
IL161942A0 (en) 2005-11-20
PL342012A1 (en) 2001-05-07
NO20003721D0 (no) 2000-07-20
AP1229A (en) 2003-12-04
SG115489A1 (en) 2005-10-28
US20020019396A1 (en) 2002-02-14
PT1047428E (pt) 2007-09-07
CA2318268A1 (fr) 1999-07-29
IS2494B (is) 2009-02-15
HUP0100900A2 (hu) 2002-05-29
HRP20000494A2 (en) 2000-12-31
ATE365042T1 (de) 2007-07-15
KR20010034285A (ko) 2001-04-25
HRP20000494B1 (en) 2009-02-28
YU67102A (sh) 2004-12-31
WO1999037305A1 (fr) 1999-07-29
AP2000001869A0 (en) 2000-09-30
NO326878B1 (no) 2009-03-09
SK10912000A3 (sk) 2001-04-09
HRP20051024A2 (hr) 2006-04-30
EA200000691A1 (ru) 2001-04-23
EP1047428A1 (fr) 2000-11-02
CN1294513A (zh) 2001-05-09
EA002410B1 (ru) 2002-04-25
NZ529316A (en) 2004-05-28
CN1255389C (zh) 2006-05-10
DE69936335T2 (de) 2008-02-28
AU2328099A (en) 1999-08-09
NZ505809A (en) 2002-09-27
ES2288012T3 (es) 2007-12-16
CY1106828T1 (el) 2012-05-23
NO20083529L (no) 2000-09-19
IS5568A (is) 2000-07-20
US6391875B2 (en) 2002-05-21
ID26334A (id) 2000-12-14
US6274579B1 (en) 2001-08-14

Similar Documents

Publication Publication Date Title
EE04452B1 (et) Farmatseutiliselt aktiivne morfolinool ja selle kasutamine
EE05169B1 (et) Asendatud oksasolidinoonid ja nende kasutamine
EE05210B1 (et) Suhkurt?vevastane preparaat ja selle kasutamine meditsiinis
DE69918074D1 (de) Makrolid-formulierung mit verzögerter wirkstoffabgabe
EE04144B1 (et) Farmatseutiline kompositsioon ja selle kasutamine
FI973816A0 (fi) Polypropen med hoeg smaeltstyrka
ID26340A (id) Kapsul ganda dengan penggunaan bahan-bahan aktif dalam berbagai macam pengobatan
ID22957A (id) Senyawa dan penggunaannya
EE200200251A (et) Uued N-asabitsükloamiidi derivaadid ja nende kasutamine
EE200200484A (et) Väikeseannuseline entekaviiripreparaat ja selle kasutamine
NO994438L (no) Terapeutisk aktive diarylpropylaminer samt fremstilling og anvendelse derav
ID26599A (id) Turunan triazola dan imidazola
ID24196A (id) Komposisi dan penggunaan
DE69916694D1 (de) 2-Hydroxy-5-methyl-hexan-3-on und 3-hydroxy-5-methyl-hexan-2-on
DE59814201D1 (de) Polybenzoxazol- und Polybenzothiazol-Vorstufen
EE03667B1 (et) Alfa -2 - adrenotseptori antagonisti, selle derivaadi kasutamine ravimi valmistamiseks vaimuhaiguseravimiseks imetajatel ja kompositsioon selle tarvis
EE200100051A (et) Vastavast (-)-stereoisomeerist põhiliselt vaba (+)-nortsisapriidi või selle farmatseutiliselt vastuvõetava soola kasutamine ja farmatseutiline kompositsioon
DE60032898D1 (de) Arylthiazolidindion- und aryloxazolidinderivate
EE03387B1 (et) Kombineeritud ravimpreparaat, selle kasutamine ja meetod selle valmistamiseks
DE59902159D1 (de) Aktiver mikromischer
EE200100305A (et) Preparaat, selle kasutamine ja valmistamismeetod
IT1291823B1 (it) Composti pseudo-peptidici, loro preparazione ed uso in formulazioni farmaceutiche
FI982682A (fi) Uusi komposiitti ja sen käyttö
EE200200096A (et) IREN-valk, selle valmistamine ja kasutamine
EE200200168A (et) PRV-1-geen ja selle kasutamine

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20130120